Developer docs
API playgroundTry for free, no card

Search company profiles

Celentyx

Full company profile

uuid00094tr

Namestring
Celentyx
Legal namestring
Celentyx Ltd
Websiteurl
celentyx.com
Company typeenum
Private
Founded yearint
2007
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBirmingham, United Kingdom
HQ citystring
Birmingham
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract research organization, immunology assay services, preclinical drug discovery, immuno-oncology research, human primary cell assays
Industry2 codes
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
NAICS code2 codes
  • Testing Laboratories and Services54138
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Contract Research Services (Immunology CRO)
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Contract Research Services
TypeProfessional Services
Description

Bespoke assay services in human immunology delivered to pharmaceutical and biotech clients for drug discovery programs. Services include assay development, screening, and characterization studies performed on a fee-for-service basis.

celentyx.com
2Bespoke Assay Development
TypeProfessional Services
Description

Custom assay design and development services tailored to specific client drug discovery needs, from study design through optimization to interpretation.

celentyx.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Celentyx is a Contract Research Organization (CRO) that delivers bespoke immunology assay services for pharmaceutical and biotech drug discovery programs. The company uses patient and healthy donor primary cells and tissues to run in vitro assays spanning immuno-oncology, autoimmunity and inflammation, fibrosis, neuroinflammation, and COVID-19, supported by platform technologies including flow cytometry, CyTOF, Luminex, ELISA, high-content imaging, and 3D spheroid models. Services include candidate selection, medium-throughput screening, mechanism-of-action studies, target discovery, and proof-of-concept studies delivered on a fee-for-service basis.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Over 2000 citations for CEO's research paper, indicating scientific leadership and credibility
Product overview1 text field

Celentyx is a Contract Research Organization (CRO) offering bespoke immunology assay services. The company provides a comprehensive portfolio of immune cell-based assay services organized across four therapeutic areas: Immuno-Oncology, Autoimmunity & Inflammation, Fibrosis, and Neuroinflammation. The core offerings include specialized cell-based assays (T cell exhaustion, T cell activation, tumour cell killing, NK cell assays, B cell assays, macrophage/monocyte assays, microglia assays, neutrophil assays, phagocytosis assays, fibroblast assays, regulatory T cell assays, suppression assays, TIL assays, antigen-specific assays, and haemolysis testing) combined with technology platforms (Flow Cytometry, CyTOF, Luminex, ELISA, ELISpot, ELLA, Cytokine Release Assays, Intracellular Cytokine Staining, Phosphoflow, Seahorse Metabolic Assays, and High-Content Imaging). Additional services include assays on patient cells and bespoke assay development. The company operates laboratories in Birmingham and Oxford, UK.

Product and service7 records
1Immuno-Oncology Assays
CategoryImmuno-Oncology CRO Services
Description

In vitro assay services for immuno-oncology drug discovery using human primary immune cells, profiling T cell exhaustion, suppression, tumour cell killing, and dissociated human tumours. For pharmaceutical and biotech companies developing checkpoint inhibitors, bispecific antibodies, CAR-T cells, and other immuno-modulatory therapeutics.

2Autoimmunity & Inflammation Assays
CategoryAutoimmunity & Inflammation CRO Services
Description

Assay services supporting therapeutic development for autoimmune and inflammatory diseases using human immune cells from healthy volunteers or patients, measuring proliferation, cytokine and chemokine release, cell migration, and phagocytosis. For pharmaceutical and biotech teams developing treatments for rheumatoid arthritis, psoriasis, SLE, and related conditions.

3Fibrosis Assays
CategoryFibrosis CRO Services
Description

In vitro fibrosis drug validation services including Smad3 signalling, extracellular matrix accumulation, and collagen gel contraction assays using human fibroblasts. For pharmaceutical and biotech companies developing anti-fibrotic therapeutics for idiopathic pulmonary fibrosis, liver fibrosis, corneal scarring, and burns.

4Neuroinflammation Assays
CategoryNeuroinflammation CRO Services
Description

In vitro neuroinflammation drug validation using human cellular models to probe cytokine/biomarker release from astrocytes and microglia, plus electrophysiology, intracellular calcium measurements, cell chemotaxis, phagocytosis, and autoantibody binding. For pharmaceutical and biotech teams developing therapeutics for neurodegenerative and psychiatric disorders with neuroinflammatory components including Alzheimer's, Parkinson's, schizophrenia, and depression.

5COVID-19 Assays
CategoryCOVID-19 CRO Services
Description

Cell-based ACE2/SARS-CoV-2 spike-binding high-throughput imaging assays for identification of small molecule or antibody inhibitors of spike binding. Developed and delivered in collaboration with the Universities of Birmingham and Warwick, with co-funding from Innovate UK.

6Bespoke Assay Development
CategoryBespoke CRO Services
Description

Customized assay design and development services for immunological and cell biological assays, covering background data review, study design, optimization, and interpretation. Delivered on a fee-for-service basis to pharmaceutical and biotech teams with unique or non-standard pre-clinical questions.

7Assays on Patient Cells
CategoryPatient Sample CRO Services
Description

Assay services performed on cells and tissues obtained from patient blood and tissue through strategic hospital relationships, compatible with flow cytometry, imaging, and multiplex biomarker quantification. Enables pharmaceutical and biotech clients to assess drug impact on patient cells with physiologically relevant samples, processed within hours of isolation.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
1Meiji Seika Kaisha, Ltd
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Celentyx entered into agreement with Meiji Seika Kaisha in August 2009 to discover new development paths for Meiji drug candidates using Celentyx's Novel Clinical Indication Profiling™ technology.

celentyx.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Announced Immuno-Profiling™ collaboration with natural products drug company Hypha Discovery in July 2009.

3AMRI
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Continued collaboration with AMRI, including joint data presentations at British Pharmacological Society Winter Meeting 2008 and Serotonin Club Meeting 2008.

celentyx.com
4Alfama Inc
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration announced with Alfama Inc in October 2008.

celentyx.com
5Schering-Plough
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration announced with Schering-Plough in January 2008 for immunology research services.

celentyx.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration demonstrating benefit of immune-modulatory drug for immuno-compromised individuals and patients with viral infection, published January 2017.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Close association with MRC Centre for Immune Regulation at University of Birmingham enables access to world-leading immunology expertise and translational research capabilities.

8Centre for Translational Inflammation Research
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic relationship with Centre for Translational Inflammation Research supporting investigation of human immune system in health and disease.

celentyx.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Founders from University of Birmingham; company benefits from neighbouring MRC Centre for Immune Regulation and Institute of Translational Medicine; collaborations for COVID-19 drug discovery with Universities of Birmingham and Warwick.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Cell therapy and immunology services provider including cell-based assays and preclinical development — comparable to Celentyx in cell-based assay services for immuno-oncology and cell therapy sponsors.

TypeRegional player
Description

Nordic-based specialty CRO with strong immunology and cell-based assay offerings — comparable service portfolio to Celentyx though primarily serving European pharma/biotech.

TypeBroad incumbent
Description

Large global CRO providing discovery and preclinical services including immunology, in vivo pharmacology, and cell-based assays — overlaps with Celentyx's preclinical immunology offerings but at much greater scale and breadth.

TypeBroad incumbent
Description

Integrated CRO with preclinical, biologics, and immunology services — competes for larger pharma R&D budgets including cell-based immunology assays adjacent to Celentyx's offering.

TypeDirect peer
Description

Specialty CRO focused on human primary cell-based assays for hematology and immunology drug discovery — closely comparable niche positioning to Celentyx, serving pharma with bespoke cell-based assay services.

6Cellero (HemaCare)
TypeOthers
Description

Provider of fresh and cryopreserved human primary immune cells for research and preclinical use — adjacent enabling supplier to Celentyx's patient-cell-based assay workflow.

TypeBroad incumbent
Description

Major preclinical CRO offering immunology, cell-based assays, and safety assessment; competes with Celentyx for immunology drug discovery budgets, though typically for larger enterprise engagements.

TypeDirect peer
Description

Specialized bioanalytical and immunology-focused CRO offering immunoassays, cell-based assays, and biomarker services to pharma/biotech — directly comparable to Celentyx's human immunology assay services and therapeutic-area focus.

TypeDirect peer
Description

Immunology-focused CRO providing in vitro immunology assays including T cell, B cell, and innate immune cell assays using human cells — directly comparable service offering to Celentyx's assay menu.

TypeEmerging player
Description

Specialty CRO offering protein-based drug discovery and cell biology services, including immuno-oncology assays — partial overlap with Celentyx's immuno-oncology assay portfolio.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Celentyx

Contract Research Services (Immunology CRO)celentyx.com

Celentyx firmographics

Firmographics
Name
Celentyx
Legal name
Celentyx Ltd
Website
https://celentyx.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Celentyx industry classification

Industry
Product category
Contract Research Services (Immunology CRO)
NAICS
Testing Laboratories and Services (54138), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)

Keywords

  • Contract research organization
  • Immunology assay services
  • Preclinical drug discovery
  • Immuno-oncology research
  • Human primary cell assays

Where Celentyx is headquartered

Location

Headquarters

HQ city
Birmingham
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Celentyx business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Contract Research Services: Bespoke assay services in human immunology delivered to pharmaceutical and biotech clients for drug discovery programs. Services include assay development, screening, and characterization studies performed on a fee-for-service basis.
  2. Bespoke Assay Development: Custom assay design and development services tailored to specific client drug discovery needs, from study design through optimization to interpretation.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Celentyx product offering

Product offering

Core offering

Celentyx is a Contract Research Organization (CRO) that delivers bespoke immunology assay services for pharmaceutical and biotech drug discovery programs. The company uses patient and healthy donor primary cells and tissues to run in vitro assays spanning immuno-oncology, autoimmunity and inflammation, fibrosis, neuroinflammation, and COVID-19, supported by platform technologies including flow cytometry, CyTOF, Luminex, ELISA, high-content imaging, and 3D spheroid models. Services include candidate selection, medium-throughput screening, mechanism-of-action studies, target discovery, and proof-of-concept studies delivered on a fee-for-service basis.

Product overview

Celentyx is a Contract Research Organization (CRO) offering bespoke immunology assay services. The company provides a comprehensive portfolio of immune cell-based assay services organized across four therapeutic areas: Immuno-Oncology, Autoimmunity & Inflammation, Fibrosis, and Neuroinflammation. The core offerings include specialized cell-based assays (T cell exhaustion, T cell activation, tumour cell killing, NK cell assays, B cell assays, macrophage/monocyte assays, microglia assays, neutrophil assays, phagocytosis assays, fibroblast assays, regulatory T cell assays, suppression assays, TIL assays, antigen-specific assays, and haemolysis testing) combined with technology platforms (Flow Cytometry, CyTOF, Luminex, ELISA, ELISpot, ELLA, Cytokine Release Assays, Intracellular Cytokine Staining, Phosphoflow, Seahorse Metabolic Assays, and High-Content Imaging). Additional services include assays on patient cells and bespoke assay development. The company operates laboratories in Birmingham and Oxford, UK.

Differentiator

Problem solved

Functional benefit

Products and services

  • Immuno-Oncology Assays In vitro assay services for immuno-oncology drug discovery using human primary immune cells, profiling T cell exhaustion, suppression, tumour cell killing, and dissociated human tumours. For pharmaceutical and biotech companies developing checkpoint inhibitors, bispecific antibodies, CAR-T cells, and other immuno-modulatory therapeutics.
  • Autoimmunity & Inflammation Assays Assay services supporting therapeutic development for autoimmune and inflammatory diseases using human immune cells from healthy volunteers or patients, measuring proliferation, cytokine and chemokine release, cell migration, and phagocytosis. For pharmaceutical and biotech teams developing treatments for rheumatoid arthritis, psoriasis, SLE, and related conditions.
  • Fibrosis Assays In vitro fibrosis drug validation services including Smad3 signalling, extracellular matrix accumulation, and collagen gel contraction assays using human fibroblasts. For pharmaceutical and biotech companies developing anti-fibrotic therapeutics for idiopathic pulmonary fibrosis, liver fibrosis, corneal scarring, and burns.
  • Neuroinflammation Assays In vitro neuroinflammation drug validation using human cellular models to probe cytokine/biomarker release from astrocytes and microglia, plus electrophysiology, intracellular calcium measurements, cell chemotaxis, phagocytosis, and autoantibody binding. For pharmaceutical and biotech teams developing therapeutics for neurodegenerative and psychiatric disorders with neuroinflammatory components including Alzheimer's, Parkinson's, schizophrenia, and depression.
  • COVID-19 Assays Cell-based ACE2/SARS-CoV-2 spike-binding high-throughput imaging assays for identification of small molecule or antibody inhibitors of spike binding. Developed and delivered in collaboration with the Universities of Birmingham and Warwick, with co-funding from Innovate UK.
  • Bespoke Assay Development Customized assay design and development services for immunological and cell biological assays, covering background data review, study design, optimization, and interpretation. Delivered on a fee-for-service basis to pharmaceutical and biotech teams with unique or non-standard pre-clinical questions.
  • Assays on Patient Cells Assay services performed on cells and tissues obtained from patient blood and tissue through strategic hospital relationships, compatible with flow cytometry, imaging, and multiplex biomarker quantification. Enables pharmaceutical and biotech clients to assess drug impact on patient cells with physiologically relevant samples, processed within hours of isolation.

Quantifiable outcome

  • Over 2000 citations for CEO's research paper, indicating scientific leadership and credibility

Companies that use Celentyx

Customer profile

Segments4 records

Ideal customer profiles4 records

Celentyx technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Celentyx partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered minor and core.

  • Meiji Seika Kaisha, LtdminorStrategic or Co-development PartnerCelentyx entered into agreement with Meiji Seika Kaisha in August 2009 to discover new development paths for Meiji drug candidates using Celentyx's Novel Clinical Indication Profiling™ technology.
  • Hypha DiscoveryminorStrategic or Co-development PartnerAnnounced Immuno-Profiling™ collaboration with natural products drug company Hypha Discovery in July 2009.
  • AMRIminorStrategic or Co-development PartnerContinued collaboration with AMRI, including joint data presentations at British Pharmacological Society Winter Meeting 2008 and Serotonin Club Meeting 2008.
  • Alfama IncminorStrategic or Co-development PartnerCollaboration announced with Alfama Inc in October 2008.
  • Schering-PloughminorStrategic or Co-development PartnerCollaboration announced with Schering-Plough in January 2008 for immunology research services.
  • ImmcellminorStrategic or Co-development PartnerCollaboration demonstrating benefit of immune-modulatory drug for immuno-compromised individuals and patients with viral infection, published January 2017.
  • MRC Centre for Immune RegulationcoreStrategic or Co-development PartnerClose association with MRC Centre for Immune Regulation at University of Birmingham enables access to world-leading immunology expertise and translational research capabilities.
  • Centre for Translational Inflammation ResearchcoreStrategic or Co-development PartnerStrategic relationship with Centre for Translational Inflammation Research supporting investigation of human immune system in health and disease.
  • University of BirminghamcoreStrategic or Co-development PartnerFounders from University of Birmingham; company benefits from neighbouring MRC Centre for Immune Regulation and Institute of Translational Medicine; collaborations for COVID-19 drug discovery with Universities of Birmingham and Warwick.

Scale indicators3 records

Recent moves7 records

Expansion highlights4 records

Celentyx competitors and assessment

Company assessment

Broad incumbents

  • GenScript ProBio: Cell therapy and immunology services provider including cell-based assays and preclinical development — comparable to Celentyx in cell-based assay services for immuno-oncology and cell therapy sponsors.
  • Eurofins Discovery: Large global CRO providing discovery and preclinical services including immunology, in vivo pharmacology, and cell-based assays — overlaps with Celentyx's preclinical immunology offerings but at much greater scale and breadth.
  • Pharmaron: Integrated CRO with preclinical, biologics, and immunology services — competes for larger pharma R&D budgets including cell-based immunology assays adjacent to Celentyx's offering.
  • Charles River Laboratories: Major preclinical CRO offering immunology, cell-based assays, and safety assessment; competes with Celentyx for immunology drug discovery budgets, though typically for larger enterprise engagements.

Regional players

  • Svar Life Science: Nordic-based specialty CRO with strong immunology and cell-based assay offerings — comparable service portfolio to Celentyx though primarily serving European pharma/biotech.

Direct peers

  • ReachBio Research Labs: Specialty CRO focused on human primary cell-based assays for hematology and immunology drug discovery — closely comparable niche positioning to Celentyx, serving pharma with bespoke cell-based assay services.
  • BioAgilytix: Specialized bioanalytical and immunology-focused CRO offering immunoassays, cell-based assays, and biomarker services to pharma/biotech — directly comparable to Celentyx's human immunology assay services and therapeutic-area focus.
  • ImmunXperts (Cenya): Immunology-focused CRO providing in vitro immunology assays including T cell, B cell, and innate immune cell assays using human cells — directly comparable service offering to Celentyx's assay menu.

Others

  • Cellero (HemaCare): Provider of fresh and cryopreserved human primary immune cells for research and preclinical use — adjacent enabling supplier to Celentyx's patient-cell-based assay workflow.

Emerging players

  • Proteros: Specialty CRO offering protein-based drug discovery and cell biology services, including immuno-oncology assays — partial overlap with Celentyx's immuno-oncology assay portfolio.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Celentyx social profiles

Digital presence

Celentyx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Celentyx leadership team

Management profile

Number of profiles

Profiles8 records

Celentyx funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Celentyx M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Celentyx

What does Celentyx do?

Celentyx is a Contract Research Organization (CRO) that delivers bespoke immunology assay services for pharmaceutical and biotech drug discovery programs. The company uses patient and healthy donor primary cells and tissues to run in vitro assays spanning immuno-oncology, autoimmunity and inflammation, fibrosis, neuroinflammation, and COVID-19, supported by platform technologies including flow cytometry, CyTOF, Luminex, ELISA, high-content imaging, and 3D spheroid models. Services include candidate selection, medium-throughput screening, mechanism-of-action studies, target discovery, and proof-of-concept studies delivered on a fee-for-service basis.

Is Celentyx a public or private company?

Celentyx is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Celentyx founded?

Celentyx was founded in 2007. It employs 11 to 50 people.

Where is Celentyx based?

Celentyx is headquartered in Birmingham, United Kingdom, in the Europe region.

How does Celentyx make money?

Two revenue lines are on record. Contract Research Services are the primary driver. The others are bespoke Assay Development.

Who are Celentyx's main competitors?

Broad incumbents on record are GenScript ProBio, Eurofins Discovery, Pharmaron and Charles River Laboratories. Svar Life Science is listed as a regional player. Direct peers are ReachBio Research Labs, BioAgilytix and ImmunXperts (Cenya). Cellero (HemaCare) is listed as an others. Proteros is listed as an emerging player.

Does Celentyx have an API?

No public API is recorded for Celentyx.

What industry is Celentyx in?

Celentyx's product category is Contract Research Services (Immunology CRO). Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 54138 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales